Labiana Health, S.A. (BME:LAB)

Market Cap	52.28M +89.4%
Revenue (ttm)	76.44M +13.5%
Net Income	2.57M +913.7%
EPS	0.37
Shares Out	8.30M
PE Ratio	17.24
Forward PE	8.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	6.30
Previous Close	6.30
Day's Range	6.25 - 6.30
52-Week Range	3.92 - 8.20
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 21, 2026

About Labiana Health

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, the company offers contract developments, qua...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1958
• Employees: 373
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: LAB

Financial Performance

In 2025, Labiana Health's revenue was 76.44 million, an increase of 13.46% compared to the previous year's 67.37 million. Earnings were 2.57 million, an increase of 913.67%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error